A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.
iPS 細胞による腎再生医療・創薬の研究開発を行うバイオベンチャー企業、リジェネフロ株式会社（本 社：京都府京都市、代表取締役：森中 紹文）は、J-KISS 型新株予約権の発行により、ファーストクローズとして総...
[画像1: https://prtimes.jp/i/129258/6/resize/d129258-6-e5e54f74b7be7e715bd2-7.jpg ] リジェネフロ株式会社(本社:京都市、代表取締役:森中紹文、以下当社)は、この度、シリーズBラウンドを実施し、DCIパート...
リジェネフロ株式会社(https://www.regenephro.co.jp/)は、タミバロテンをADPKD治療薬開発品(RN-014)とした前期第二相臨床試験の第２段階の被験者募集を4月より開始いたしました。本件は昨年12月より開始した第1...
1）要旨 京大発スタートアップ企業のリジェネフロ株式会社（本社：京都市左京区、代表取締役：森中紹文、以下「リジェネフロ」）は、京都大学iPS細胞研究所（本部：京都市左京区、所長: 高橋淳、以下「CiRA」）...
[画像1: https://prtimes.jp/i/129258/3/resize/d129258-3-0adf9dac121bc59fe0f3-0.jpg ] 本共同研究でリジェネフロとCiRAは、1) iPS細胞由来の遺伝子改変により治療効果に関わる機能を強化し、免疫抑制剤を不...
ADPKDとは、両側の腎臓に多数の嚢胞が次第に発生・増大し、徐々に腎機能障害が進行する遺伝性の難病であり、人工透析や腎移植を必要とする末期腎不全に至ります。腎臓以外にも、肝臓や膵臓などに嚢胞が生じるこ...
A startup developing a childcare support app that analyzes baby cries using AI to visualize emotions. Contributing to reducing childcare stress and preventing postpartum depression through consumer and corporate employee benefits SaaS, while also advancing international expansion.
Visualizing the mind and body to spark behavioral change. Evcare is dedicated to advancing human well-being through cutting-edge hormone measurement technology derived from academic research. We specialize in analyzing biomarkers found in hair, nails, and saliva. Our core services include: R&D Support: Accelerating product development with scientific evidence. Corporate Wellness: Providing objective stress checks based on physiological data, moving beyond subjective surveys to true health visualization.
A startup developing 3D game-based medical devices to comprehensively assess and treat executive function in children with ADHD. By combining game design with neuroscience, it advances digital transformation in healthcare and expands possibilities for supporting diverse children.
HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.